Xenotransplanted Human Prostate Carcinoma (DU145) Cells Develop into Carcinomas and Cribriform Carcinomas: Ultrastructural Aspects

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 61:10–29.
   Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK. Cancer in the United Kingdom, April 2011. Cancer Res UK; info.cacerresearchUK.org/
   Google Scholar
• Miller DC, Zheng SL, Dunn RL, et al. Berm-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res. 2003; 63: 3486–3489.
   PubMed Web of Science ®Google Scholar
• Bock CH, Schwartz AG, Rutterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African American men. Hum Genet. 2009; 26: 637–647.
   Google Scholar
• Gilloteaux J, Jamison JM, Neal D, Arnold D, Summers JL. Human prostate DU145 carcinoma cells implanted in nude mice displace the peritoneal mesothelium to grow invasively as solid and cribriform carcinomas. Anat Rec. 2012; submitted.
   Google Scholar
• Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 1977; 37: 4049–4058.
   PubMed Web of Science ®Google Scholar
• Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF. Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res. 1980; 37: 67–84.
   PubMedGoogle Scholar
• Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978; 21: 274–281.
   PubMed Web of Science ®Google Scholar
• Cohen MB, Heidger PM, Lubaroff DM. Gross and microscopic pathology of indiced pprostatic complex tumors arising in Lobund-Wistar rats. Cancer Res. 1994; 54: 626–628.
   PubMedGoogle Scholar
• Dhom G. Prostata. In: Hedinger CE, Dhom G, eds. Pathologie des männlichen Genitale. Berlin: Springer; 1991: 458–642 and 548–553.
   Google Scholar
• Ahn SK, Kim K, Choi IJ, Lee JM. 1991. Adenoid cystic carcinoma of the prostate gland. Yonsei Med J 32: 74–78.
   PubMedGoogle Scholar
• Montironi R, Mazzucchelli R, Algaba F, Lopez-Beltran A. Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol. 2000; 53: 655–665.
   PubMed Web of Science ®Google Scholar
• Shin M, Takayama H, Nonomura N, Wakatsuki, Okuyama A, Aozasa K. Extend and zonal distribution of prostatic intraepithelial neoplasia in patient with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens. The Prostate. 2000; 42: 81–87.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Liu L, Brawer MK. High-grade prostatic intraepithelial neoplasia. Rev Urol. 2004;6: 171–179.
   PubMedGoogle Scholar
• Epstein JI. Precursor lesions to prostatic adenocarcinoma. Virchows Arch. 2009; 454: 1–16.
   PubMed Web of Science ®Google Scholar
• Dema A, Borda A, Lazar E, et al. Prostate lesions with cribriform/pseudocribriform pattern. Rom J Morph Embryol. 2010; 51: 413–425.
   PubMed Web of Science ®Google Scholar
• Taper HS, Jamison JM, Gilloteaux J, Gwin CA, Gordon T, Summers JL. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C:K3 J Histochem Cytochem. 2001; 49: 109–119.
   PubMed Web of Science ®Google Scholar
• Gilloteaux J, Jamison JM, Venugopal M, Giammar D, Summers JL. Scanningelectron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C–vitamin K3 combinations against human prostatic carcinoma cells. Scanning Microsc. 1995; 9:159–173.
   PubMedGoogle Scholar
• Aparicio SR, Marsden P. Application of standard micro-anatomical staining methods to epoxy resin-embedded sections. J Clin Pathol. 1969; 22: 589–592.
   PubMed Web of Science ®Google Scholar
• Jamison JM, Gilloteaux J, Venugopal M, et al. Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C–vitamin K3 combinations against human prostatic carcinoma cells. Tissue Cell. 1996; 28:687–701
   PubMed Web of Science ®Google Scholar
• Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic antitumour activity of vitamins C and K3 against human prostate carcinoma cell lines. Cell Biol Int. 1996; 20:787–797.
   PubMed Web of Science ®Google Scholar
• Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic antitumor activity of vitamins C and K3 on human urologic tumor cell lines. Life Sci. 1996;59(17):1389–1400.
   PubMed Web of Science ®Google Scholar
• Jamison JM, Gilloteaux J, Neal D, Summers JL. Characterization of the early events in vitamin C and K3-induced death of human prostate tumor cells. Scanning. 1999; 21: 107–108.
   Web of Science ®Google Scholar
• Gilloteaux J, Jamison JM, Neal DR, Summers JL. Cell death by autoschizis in TRAMP prostate carcinoma cells as a result of treatment by ascorbate: menadione combination. Ultastruct Pathol. 2005; 29: 221–235.
   PubMed Web of Science ®Google Scholar
• Jamison JM, Gilloteaux J, Taper HS, et al. The in vitro and in vivo antitumor activity of vitamin C:K3 combinations against prostate cancer. In: Lucas JL, ed. Prostate Cancer. Hauppauge, NY: Nova Science; 2005: 423–471.
   Google Scholar
• Doré JF, Bailly M, Bertrand S. Metastases of human tumors in experimental animals. Anticancer Res. 1987; 7:997–1003.
   PubMed Web of Science ®Google Scholar
• Kubota T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem. 1994; 56:4–8.
   PubMed Web of Science ®Google Scholar
• Turner T, Chen P, Goodly LJ, Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis. 1996;14: 409–418.
   PubMed Web of Science ®Google Scholar
• Turner T, VanEpps-Fung M, Kassis J, Wells A. Molecular inhibition of PLCγ signaling abrogates DU-145 prostate tumor cell invasion. Clin Cancer Res. 1997;3: 2275–2282.
   PubMed Web of Science ®Google Scholar
• Pretlow TG, Schwartz S, Giaconia JM, et al. Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res. 2000; 60: 4033–4036.
   PubMed Web of Science ®Google Scholar
• Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003; 253:89–101.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Park ES, Soloff MS. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol. 2004; 11:876–884.
   PubMed Web of Science ®Google Scholar
• Chunthapong J, Seftor EA, Khalkhali-Ellis Z, et al. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem. 2004; 91: 649–661.
   PubMed Web of Science ®Google Scholar
• Mamoune A, Kassis J, Kharait S, et al. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Exp Cell Res. 2004; 299: 91–100.
   PubMed Web of Science ®Google Scholar
• Oosterhoff JK, Kühne LC, Grootegoed JA, Blok LJ. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer. 2005; 113: 561–567.
   PubMed Web of Science ®Google Scholar
• Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone. 2007; 40: 981–990.
   PubMed Web of Science ®Google Scholar
• Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 2008 Dec;99(12):2467–2476.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 2010; 12:841–852.
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Margaryan NV, Loessner D, et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate. 2011; 71:1198–1209.
   PubMed Web of Science ®Google Scholar
• Rybak AP, He L, Kapoor A, Cutz JC, Tang D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta. 2011; 181: 683–694.
   Google Scholar
• Shanmugam MK, Rajendran P, Li F, et al. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J Mol Med. 2011; 89: 713–727.
   PubMed Web of Science ®Google Scholar
• Willis RA. Pathology of Tumors. Washington, DC: Butterworths; 1960: 148–166.
   Google Scholar
• Drasdo D, Höhme S. Individual-based approaches to birth and death in avascular tumors. Mathl Comput Modelling. 2003; 37: 1163–1175.
   Google Scholar
• Kaminski A, Hahne JC, Haddouti E, Florin A, Wellmann A, Wernert N. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med. 2006;18: 941–950
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet.1995; 9: 401–406.
   PubMed Web of Science ®Google Scholar
• Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006; 580:2294–3000.
   PubMed Web of Science ®Google Scholar
• Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate. 2011; 71:1595–1607.
   PubMed Web of Science ®Google Scholar
• Ligęza J, Ligęza J, Klein A. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells. Acta Biochim Pol. 2011; 58: 391–396.
   PubMed Web of Science ®Google Scholar
• Higgins LH, Withers HG, Garbens A, et al. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta. 2009; 1787:1433–1443
   PubMed Web of Science ®Google Scholar
• Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2011; 81: 521–528.
   PubMed Web of Science ®Google Scholar
• Guo Z, He Y, Wang S, et al. Various effects of hepatoma-derived growth factor on cell growth, migration, and invasion of breast cancer and prostate cancer cells. Oncol Rep. 2011; 26: 511–517.
   PubMed Web of Science ®Google Scholar
• Qu-Hong JA, Nagy DR, Senger HF, Dvorak HF, Dvorak AM. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem. 1995; 43: 381–389.
   PubMed Web of Science ®Google Scholar
• Peng YB, Zhou J, Gao Y, et al. Normal prostate-derived stromal cells stimulate prostate cancer development. Cancer Sci. 2011; 102: 1630–1635.
   PubMed Web of Science ®Google Scholar
• Nguyen HL, Zucker S, Zarrabi K, Kadam P, Schmidt C, Cao J. Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase. Mol Cancer Res. 2011; 9: 1305–1318.
   PubMed Web of Science ®Google Scholar
• Ksiazek K, Mikuła-Pietrasik J, Catar R, et al. Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int J Cancer. 2010; 127: 293–303.
   PubMed Web of Science ®Google Scholar
• Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993; 85: 1657–1669.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275:1943–1947.
   PubMed Web of Science ®Google Scholar
• Li Y, Su J, DingZhang X, et al. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. J Pathol. 2011; 224: 90–100.
   PubMed Web of Science ®Google Scholar
• Vo BT, Khan SA. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate. 2011;71:1084–1096.
   PubMed Web of Science ®Google Scholar
• D’Antonio KB, Schultz L, Albadine R, et al. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res. 2010; 16: 5908–5913.
   Google Scholar
• Abdulghani J, Gu L, Dagvadorj A, et al. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008; 72:1717–1728.
   Google Scholar
• Gerstein AV, Almeida TA, Zhao G, et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer. 2002; 34: 9–16.
   PubMed Web of Science ®Google Scholar
• Park ER, Pullikuth AK, Bailey EM, Mercante DE, Catling AD. Differential requirement for MEK Partner 1 in DU145 prostate cancer cell migration. Cell Commun Signal. 2009; 7:26.
   PubMed Web of Science ®Google Scholar
• Colella R, Jackson T, Goodwyn E. Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L+B activity. Biotech Histochem. 2004; 79:121–127.
   PubMed Web of Science ®Google Scholar
• Wu W, Walker AM. Human chorionic gonadotropin beta (HCGbeta) down-regulates E-cadherin and promotes human prostate carcinoma cell migration and invasion. Cancer.2006; 106: 68–78.
   PubMed Web of Science ®Google Scholar
• Ko YH, Ha YR, Kim JW, et al. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145. J Int Med Res. 2011; 39: 729–739.
   PubMed Web of Science ®Google Scholar
• Shimoyama Y, Hiroshashi S, Hirano S, et al. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 1989; 49: 2128–2133.
   PubMed Web of Science ®Google Scholar
• Gilloteaux J. Les connexions intercellulaires d’un muscle lisse: ultrastructure du muscle rétracteur anterieur du byssus (ABRM) de Mytilus edulis L. (Mollusca Pelecypoda). Cytobiologie (previously Eur J Cell Biol). 1976; 12, 456–472.
   Google Scholar
• Shapiro L, Fannon AM, Kwong PD, et al. Structural basis of cell-cell adhesion by Cadherins. Nature. 1995; 374: 327–337.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 2001; 32: 690–697.
   PubMed Web of Science ®Google Scholar
• Paul R, Ewing CM, Jarrard DF, Isaacs WB. The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol. 1997; 1: 37–43.
   Google Scholar
• De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology. 1999; 53:707–713.
   PubMed Web of Science ®Google Scholar
• Umbas R, Isaaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54: 3929–3933.
   PubMed Web of Science ®Google Scholar
• Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG. Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 1996; 148: 1375–1380.
   PubMed Web of Science ®Google Scholar
• Rios-Doria J, Day KC, Kuefer R, et al. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem. 2003; 278: 1372–1379.
   PubMed Web of Science ®Google Scholar
• Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer. 1994; 69:580–585
   PubMed Web of Science ®Google Scholar
• Kuefer R, Hofer MD, Gschwend JE, et al. The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res. 2003; 9: 6447–6452.
   PubMed Web of Science ®Google Scholar
• Kuefer R, Hofer MD, Zorn CS, et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. 2005; 92: 2018–2023.
   PubMed Web of Science ®Google Scholar
• Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res. 1993; 53:3585–3590.
   PubMed Web of Science ®Google Scholar
• Morita N, Uemura H, Tsumatani K, et al. E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer. 1999; 79:1879–1883.
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Kärjä V, Lipponen P, et al. Reduced alpha- and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res. 2005; 25:4707–4712.
   PubMed Web of Science ®Google Scholar
• Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene. 2007 Apr 5;26(16):2290–2298.
   PubMed Web of Science ®Google Scholar
• Putzke AP, Ventura AP, Bailey AM, et al. Metastatic progression of prostate cancer and E-cadherin regulation by zeb1 and STRc family kinases. Am J Pathol. 2011; 179: 400–410.
   PubMed Web of Science ®Google Scholar
• Tran NL, Nagle RB, Cress AE, Heimark RL. N-cadherin expression in human prostatecarcinoma cell lines: an epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol. 1999; 155: 787–798.
   PubMed Web of Science ®Google Scholar
• Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007; 13: 7003–7011.
   PubMed Web of Science ®Google Scholar
• Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocrin Relat Cancer. 2010;17: 469–479.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody targeting N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010; 16: 1414–1420.
   PubMed Web of Science ®Google Scholar
• Kümper S, Ridley AJ. P120ctn and P-cadherin but not E-cadherin regulate cell motility and invasion of DU145 prostate cancer cells. PLos One. 2010; 5: e11801.
   PubMed Web of Science ®Google Scholar
• Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rübben H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res. 1993; 21:359–362.
   PubMedGoogle Scholar
• Nalai AK, Estes N, Patel J, Rao JS. N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signalling in prostate cancer cells. Exp Cell Res. 2011; 317: 2511–2521.
   Web of Science ®Google Scholar
• Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17: 548–558.
   PubMed Web of Science ®Google Scholar
• Platica M, Ivan E, Holland JF, et al. A pituitary gene encodes a protein that produces differentiation of breast and prostate cancer cells. Proc Natl Acad Sci USA. 2004; 101: 1560–1565.
   PubMed Web of Science ®Google Scholar
• Park ER, Pullikuth AK, Bailey EM, Mercante DE, Catling AD. Differential requirement for MEK Partner 1 in DU145 prostate cancer cell migration. Cell Commun Signal. 2009; 7:26.
   PubMed Web of Science ®Google Scholar
• Wells CM, Whale AD, Parsons M, Masters JRW, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci. 2010; 123: 1663–1673.
   PubMed Web of Science ®Google Scholar
• Nightingale J, Chaudhary KS, Abel PD, et al. Ligand activation of the androgen receptor down regulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia. 2003; 5: 347–336.
   PubMed Web of Science ®Google Scholar
• Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as therapeutic target. Cancer Res. 2005; 65: 5153–5163.
   PubMed Web of Science ®Google Scholar
• Kuo P-L, Chen Y-H, Chen T-C, Shen, K-H, Hsu Y-L. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signalling pathway. J Cell Physiol. 2011; 226: 1224–1231.
   PubMed Web of Science ®Google Scholar
• Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer. 1994; 69: 580–585.
   PubMed Web of Science ®Google Scholar
• De Wever O, Derycke L, Hendrix A, et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis. 2007; 24: 685–697.
   PubMed Web of Science ®Google Scholar
• Foulds L. Neoplasms of the urinary tract. In: Neoplastic Development, vol. 2. London: Academic Press;1975: 163–204.
   Google Scholar
• Coman DR. Mechanisms responsible for the origin and distribution of blood-borne tumor metastases: a review. Cancer Res. 1953; 13: 397–404.
   PubMed Web of Science ®Google Scholar
• De Wever O, Pauwels P, De Craene B, et al. Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008; 130: 481–494.
   PubMed Web of Science ®Google Scholar
• Kuroda N, Toi M, Yamamoto M, et al. Immunocytochemical identification of intracytoplasmic lumens by cytokeratin typing may differentiate renal oncocytomas from chromophobe renal cell carcinomas. Histol Histopathol. 2004. 19: 23–28.
   PubMed Web of Science ®Google Scholar
• Ghadially FN. Ultrastructural Pathology of the Cell and Matrix, vol. 2. Boston: Butterworth-Heinemann; 1997:1072–1083.
   Google Scholar
• Erlandsen RA. Intracytoplasmic lumens. In: Diagnostic Transmission Electron Microscopy of Tumors. New York: Raven Press; 1994: 205–207.
   Google Scholar
• Ferguson DJ, Anderson TJ, Wells CA, Battersby S. An ultrastructural study of mucoid carcinoma of the breast: variability of cytoplasmic features. Histopathology. 1986; 10: 1219–1230.
   PubMed Web of Science ®Google Scholar
• Battifora H. Intracytoplasmic lumina in breast carcinoma: a helpful histopathologic feature. Arch Pathol. 1975;99: 614–617.
   PubMedGoogle Scholar
• Tsuchiya S. Intracytopalsmic lumina of human breast cancer- a microscopic study and practical application in cytological diagnosis. Acta Pathol Jpn. 1981;31: 45–54.
   PubMedGoogle Scholar
• Nesland JM, Holm R, Lunde S, Johannessen JV. Diagnostic problems in breast pathology: the benefit of ultrastructural and immunocytochemical analysis. Ultrastruct Pathol. 1987; 11: 293–311.
   PubMed Web of Science ®Google Scholar
• Gu CM. Intracytoplasmic lumina of benign and malignant breasts diseases—a light and electron microscopic study. Zhonghua Zhong Liu Za Zhi. 1990;12: 264–267.
   PubMedGoogle Scholar
• Sobrinho-Simões M, Johannessen JV, Gould VE. The diagnostic significance of intracytoplasmic lumina in metastatic neoplasms. Ultrastruct Pathol. 1981; 2: 327–335.
   PubMed Web of Science ®Google Scholar
• Quincey C, Raitt N, Bell J, Ellis IO. Intracytoplasmic lumina—a useful diagnostic feature of adenocarcinomas. Histopathology. 1991; 19: 83–87.
   PubMed Web of Science ®Google Scholar
• Alroy J, Pauli BU, Hayden JE, Gould VE. Intracytoplasmic lumina in bladder carcinomas. Hum Pathol. 1979; 10: 549–555.
   PubMed Web of Science ®Google Scholar
• Remy L, Marvaldi J. Origin of intracellular lumina in HT29 colonic adenocarcinoma cell line: an ultrastructural study. Virchows Arch B. 1985; 48:145–153.
   Google Scholar
• Boysen M, Reith A. 1980. Intracytoplasmic lumina with and without cilia in both normal and pathologically altered nasal mucosa. Ultrastruct Pathol. 4: 477–485.
   Google Scholar
• Ho KL, Caccamo DV, Garcia JH. Intracytoplasmic lumina in ependymomas: an ultrastructural study. Ultrastruct Pathol. 1994;18: 371–380.
   PubMed Web of Science ®Google Scholar
• Remy L. The intracellular lumen: origin, role and implications of a cytoplasmic neostructure. Biol Cell. 1986; 56:97–105.
   PubMed Web of Science ®Google Scholar
• Remy L, Marvaldi J, Rua S, Secchi J, Lechene de la Porte P. The role of intracellular lumina in the repolarization process of a colonic adenocarcinoma cell line. Virchows Arch B. 1984; 46: 297–305.
   Google Scholar
• Harris M, Vasudev KS, Anfield C, Wells S. Mucin-producing carcinomas of the breast: ultrastructural observations. Histopathology. 1978; 2:177–188.
   PubMed Web of Science ®Google Scholar
• Wahnschaffe U, Emura M, Mohr U. Development of intracytoplasmic lumina in diethylnitrosamine-induced tracheal papillomas of Syrian golden hamster. Virchows Arch B. 1997; 54: 59–66.
   Google Scholar
• Bosland MC, Prinsen MK, Dirksen TMJ, Spit BJ. Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrourea, 7,12-dimethylbenz(a)anthracene, and 3-2′-dimethyl-4-aminobisphenyl, following sequential treatment with cytoperone acetate and testosterone propionate. Cancer Res. 1990; 50: 700–709.
   PubMed Web of Science ®Google Scholar
• Dermer GB, Sherwin RP. Autoradiographic localization of glycoprotein in human breast cancer cells maintained in organ culture after incubation with [3H]fucose or [3H] glucosamine. Cancer Res. 1975; 35: 63–67.
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Ohwada, Fujimoto T. Intracytoplasmic lumina in human oviduct epithelium. Ultrastruct Pathol. 1997; 21: 163–172.
   PubMed Web of Science ®Google Scholar
• Ro JY, el-Naggar A, Ayala AG, Mody DR, Ordonez NG. Signet-ring-cell carcinoma of the prostate: electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol. 1988; 12: 453–460.
   PubMed Web of Science ®Google Scholar
• Kuroda N, Yamsaki I, Nakayama H, et al. Prostatic signet-ring cell carcinoma: case report and literature review. Pathol Int. 1999; 49: 457–461.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhang H, Chen J, Liu L, Zhou J. Pathologic diagnosis and histogenesis of primary signet ring cell carcinoma of the prostate. Zhonghua Bingh Li Xue Za Zhi. 2002; 31: 514–517.
   PubMedGoogle Scholar
• Leong Fj, Leong As, Swift J. Signet-ring carcinoma of the prostate. Pathol Res Pract. 1996; 192: 1232–1238.
   PubMed Web of Science ®Google Scholar
• Steinbrecher JS, Silverberg SG. Signet-ring cell carcinoma of the breast: the mucinous variant of infiltrating lobular carcinoma? Cancer. 1976; 37:828–840.
   PubMed Web of Science ®Google Scholar
• Garfield RE, Chacko S, Blose S. Phagocytosis by muscle cells. Lab Invest. 1975; 33:418–427.
   PubMed Web of Science ®Google Scholar
• Brouwer M, de Ley L, Feltkamp CA, Elema J, Jongsma APM. Serum-dependent ‘cannibalism’ and autodestruction in cultures of human small cell carcinoma of the lung. Cancer Res. 1984; 44: 2947–2951.
   PubMed Web of Science ®Google Scholar
• Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with Wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26: 239–257.
   PubMed Web of Science ®Google Scholar
• Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull. 1997; 53: 491–508.
   PubMed Web of Science ®Google Scholar
• Ren Y, Savill J. Apoptosis: the importance of being eaten. Cell Death Differ. 1998; 5: 563–568.
   PubMed Web of Science ®Google Scholar
• Flora PK, Gregory CD. Recognition of apoptotic cells by human macrophages: inhibition by a monocyte/macrophage-specific monoclonal antibody. Eur J Immunol. 1994; 24: 2625–2632.
   PubMed Web of Science ®Google Scholar
• Hart SP, Haslett C, Dransfield I. Recognition of apoptotic cells by phagocytes. Experientia. 1996; 52: 950–956.
   PubMedGoogle Scholar
• Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol. 2011; 223: 177–194.
   PubMed Web of Science ®Google Scholar
• Overholtzer, M, Mailleux AA, Mouneimne G, et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell. 2007; 131: 966–979.
   PubMed Web of Science ®Google Scholar
• Le Bot N. Entosis: cell death by invasion. Nat Cell Biol. 2007;9: 1346.
   Web of Science ®Google Scholar
• Mailleux AA, Overholtzer M, Brugge JS. L’entose, mort cellulaire par cannibalisme entre cellules tumorales. [Entosis, a cell death process related to cell cannibalism between tumor cells.] Med Sci (Paris). 2008; 24:246–248.
   PubMedGoogle Scholar
• White E. Entosis: it’s a cell-eat-cell world. Cell. 2007; 131: 840–842.
   PubMed Web of Science ®Google Scholar
• Qan Y, Shi Y. Natural killer cells go inside: entosis versus cannibalism. Cell Res. 2009; 19: 1320–1321.
   PubMed Web of Science ®Google Scholar
• Florey O, Krajcovic M, Sun Q, Overholtzer M. Entosis. Curr Biol. 2010; 20: R88–R89.
   Web of Science ®Google Scholar
• Janssen A, Medema RH. Entosis: aneuploidy by invasion. Nature Cell Biol. 2011; 13:199–201.
   PubMed Web of Science ®Google Scholar
• Yuan J, Kroemer G. Alternative cell death mechanisms in development and beyond. Genes Dev. 2011; 24: 2592–2602.
   Web of Science ®Google Scholar
• Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc Natl Acad Sci U S A. 1974; 71:4742–4746.
   PubMed Web of Science ®Google Scholar
• Lindberg U. Depolymerization of F-actin by deoxyribonuclease I. Cell. 1976 7:531–542.
   PubMed Web of Science ®Google Scholar
• Hitchcock SE. Actin deoxyroboncuclease I interaction: depolymerization and nucleotide exchange. J Biol Chem. 1980; 255: 5668–5673.
   PubMed Web of Science ®Google Scholar
• Khaitlina SY, Moraczewska J, Strzelecka-Golaszewska H. The actin/actin interactions involving the N-terminus of the DNase-I-binding loop are crucial for stabilization of the actin filament. Eur J Biochem. 1993;218: 911–920.
   PubMedGoogle Scholar
• Kabsch W, Mannherz HG, Suck D, Pai EF, Holmes KC. Atomic structure of the actin: DNase I complex. Nature. 1990; 347: 37–44.
   PubMed Web of Science ®Google Scholar
• Oztug Durer ZA, Diraviyam K, Sept D, Kudryashov DS, Reisler E. F-actin structure destabilization and DNase I binding loop: fluctuations mutational cross-linking and electron microscopy analysis of loop states and effects on F-actin. J Mol Biol. 2010; 395: 544–557.
   PubMed Web of Science ®Google Scholar
• Taper HS. Evaluation of the validity of the histochemical lead nitrate technique for alkaline and acid deoxyribonuclease. J Histochem Cytochem. 1979; 27: 1483–1490.
   PubMed Web of Science ®Google Scholar
• Taper HS. Reversibility of acid and alkaline deoxyribonuclease deficiency in malignant tumor cells. J Histochem Cytochem. 1981; 29:1053–1060.
   PubMed Web of Science ®Google Scholar
• Taper HS, Deckers CO, Deckers-Passau LO. Increase in nuclease activity as a possible means for detecting tumor cell sensitivity to anticancer agents. Cancer. 1981; 47: 523–529.
   PubMed Web of Science ®Google Scholar
• Taper HS, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pretreatment. Int J Cancer. 1987; 40: 575–579.
   PubMed Web of Science ®Google Scholar
• Amaral JB, Urabayashi MS, Machado-Santelli GM. Cell death and lumen formation in spheroids of MCF-7 cells. Cell Biol Int. 2010;34:267–274.
   PubMed Web of Science ®Google Scholar
• Montironi R, Galluzzi CM, Diamanti L, Taborro R, Scarpelli M, Pisani E. Prostatic intra-epithelial neoplasia: qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract. 1993; 189:542–548.
   PubMed Web of Science ®Google Scholar
• Gilloteaux J, Tomasello LM, Elgison DA. Lipid deposits and lipo-mucosomes in human cholecystitis and epithelial metaplasia in chronic cholecystitis. Ultrastruct Pathol. 2003; 27: 313–321.
   PubMed Web of Science ®Google Scholar
• Qian B-Z, Li J, Zhang H, et al. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumours metastasis. Nature; 475: 222–225.
   PubMed Web of Science ®Google Scholar
• Day ED. Vascular relationships of tumor and host. Prog Exp Tumor Res. 1964;4: 57–97.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011; 475: 226–230.
   PubMed Web of Science ®Google Scholar
• Wernert N, Kaminski A, Haddouti el-M, Hahne JC. Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays. Methods Mol Biol. 2007; 382: 223–237.
   PubMedGoogle Scholar
• Peng YB, Zhou J, Gao Y, et al. Normal prostate-derived stromal cells stimulate prostate cancer development. Cancer Sci. 2011; 102:1630–1635.
   PubMed Web of Science ®Google Scholar
• Reinhold HS. Improved microcirculation in irradiated tumours. Eur J Cancer.1971; 7: 273–280.
   Web of Science ®Google Scholar
• Bizik J, Kankuri E, Ristimäki E, et al. Cell–cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression. Cell Death Diff. 2004; 11, 183–195.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249–257.
   PubMed Web of Science ®Google Scholar
• Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst. 1978; 41: 1329–1341.
   Google Scholar
• Nicosia RF, Tchao R, Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res. 1983;43: 2159–2166.
   PubMed Web of Science ®Google Scholar